

REMARKS

Claims 1-14 and 17-23 are presented in this application. In this amendment, claims 15 and 16 have been cancelled, claims 1-10, 13, and 14 have been amended, and new claims 17-23 have been added. The amended claims have been amended and the newly added claims have been added to place them in form appropriate to US practice and to remove multiple dependencies for the purpose of reducing fees. Minor amendments have been made to the claims in order to conform them with the specification. No new matter has been added.

Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted in accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Entry of the amendment prior to the examination of the application and calculation of the filing fee is respectfully requested.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

/J. Scott Young/
J. Scott Young
Attorney for Applicant
Registration No. 45,582

Date: May 12, 2006
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8160
Facsimile: 919-483-7988